{"gene":"ISG20L2","run_date":"2026-04-28T18:06:54","timeline":{"discoveries":[{"year":2010,"finding":"ISG20L2 (along with ISG20L1) did not inhibit HCV replication, in contrast to ISG20, demonstrating that the closely related exonucleases lack ISG20's antiviral activity against positive-strand RNA viruses.","method":"Ectopic overexpression in cell culture with HCV replication assay","journal":"Virology","confidence":"Medium","confidence_rationale":"Tier 2 — functional cell-based assay with defined readout, single study","pmids":["21036379"],"is_preprint":false},{"year":2012,"finding":"ISG20L2 was identified as a component of human preribosomal complexes, co-immunoprecipitating with factors shared by nucleophosmin, SBDS, and NIP7 complexes, implicating ISG20L2 in ribosome biogenesis.","method":"FLAG-tagged co-immunoprecipitation followed by mass spectrometry (proteomic characterization)","journal":"Journal of proteome research","confidence":"Medium","confidence_rationale":"Tier 3 — single Co-IP/MS study; no direct functional validation of ISG20L2 role in the complex","pmids":["22540864"],"is_preprint":false},{"year":2022,"finding":"ISG20L2 directly binds bortezomib (confirmed by surface plasmon resonance) and competes with PSMB5 for bortezomib binding, thereby attenuating proteasome inhibition and conferring bortezomib resistance in multiple myeloma cells.","method":"Biotinylated bortezomib pull-down assay, surface plasmon resonance, gain- and loss-of-function studies in vitro and in vivo","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 1–2 — direct binding confirmed by SPR, competition assay, and functional KD/OE with proteasome activity readout","pmids":["36040812"],"is_preprint":false},{"year":2023,"finding":"ISG20L2 is upregulated in T lymphocytes upon TCR and type I IFN stimulation, acts as a 3'-to-5' exoribonuclease with preferential affinity for uridylated miRNA substrates, and regulates T cell activation markers (CD69, CD25, IL-2), immune synapse formation (CD3 synaptic accumulation, MTOC translocation), and expression of immunoregulatory molecules (AHR, NKG2D, CTLA-4, CD137, TIM-3, PD-L1, PD-1).","method":"ISG20L2 knockout and silencing in T cells, biochemical substrate affinity assays, flow cytometry, immune synapse imaging","journal":"Cellular and molecular life sciences : CMLS","confidence":"High","confidence_rationale":"Tier 2 — KO with multiple defined cellular phenotypes and biochemical substrate characterization, multiple orthogonal methods","pmids":["37646974"],"is_preprint":false},{"year":2024,"finding":"ISG20L2 is a 3'-5' exonuclease involved in ITS1 removal during 18S pre-rRNA maturation (in addition to previously known ITS2/5.8S rRNA processing). Crystal structure of the nuclease domain at 2.9 Å revealed a DEDDh motif (Asp183, Glu185, Asp267, His322, Asp327) with a typical αβα fold; mutagenesis mapped RNA substrate-binding residues; loss-of-function impairs ribosome biogenesis and cell proliferation.","method":"Crystal structure determination (2.9 Å), active-site mutagenesis, pre-rRNA processing assays, loss-of-function cellular proliferation assays","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with mutagenesis and functional cellular validation in a single rigorous study","pmids":["38153123"],"is_preprint":false},{"year":2025,"finding":"ISG20L2, a vertebrate-specific DEDDh RNase T superfamily member, is critical for efficient removal of the 3' external transcribed spacer (3'ETS) from pre-rRNA and for formation of large ribosomal subunits; its inactivation causes accumulation of 3'-extended pre-rRNAs and disorganization of the peripheral dense fibrillar component sub-nucleolar compartment. ISG20L2 also trims ITS1 after endonucleolytic cleavage at site 2 and contributes to 3' processing of U8 snoRNA precursor.","method":"Loss-of-function experiments combined with 3'-RACE high-throughput sequencing, nucleolar compartment imaging","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function with nucleotide-resolution sequencing and multiple orthogonal phenotypic readouts","pmids":["41261865"],"is_preprint":false},{"year":2025,"finding":"ISG20L2 promotes lung adenocarcinoma cell proliferation and invasion by modulating NKX2-1 expression, as shown by overexpression and depletion studies in A549 cells.","method":"Transient transfection overexpression/depletion, CCK-8 proliferation assay, Transwell invasion assay, flow cytometry, bioinformatics-guided target identification confirmed by cytological experiments","journal":"Translational cancer research","confidence":"Medium","confidence_rationale":"Tier 3 — single lab, functional assays with defined phenotype but limited mechanistic depth on how ISG20L2 regulates NKX2-1","pmids":["40950659"],"is_preprint":false}],"current_model":"ISG20L2 is a nucleolar 3'-to-5' DEDDh exoribonuclease (crystal structure resolved at 2.9 Å) that processes multiple pre-rRNA intermediates—including ITS1 removal during 18S maturation, 3'ETS removal required for large subunit biogenesis, and ITS2/5.8S 3'-end maturation—thereby supporting ribosome biogenesis and cell proliferation; outside the nucleolus it degrades uridylated miRNA substrates in activated T cells to regulate immune synapse formation and expression of key immunomodulatory receptors, and it can also directly bind bortezomib to compete with PSMB5 and confer proteasome-inhibitor resistance in myeloma cells."},"narrative":{"teleology":[{"year":2010,"claim":"Establishing functional divergence from ISG20: despite sequence homology, ISG20L2 lacks the antiviral exonuclease activity of ISG20, delimiting it as functionally distinct from the broader ISG20 family.","evidence":"Ectopic overexpression in cell culture with HCV replication readout","pmids":["21036379"],"confidence":"Medium","gaps":["Single virus system (HCV); antiviral activity against other viral classes not tested","Endogenous substrates of ISG20L2 remained unidentified"]},{"year":2012,"claim":"Placing ISG20L2 in the ribosome biogenesis pathway: proteomic identification of ISG20L2 in preribosomal complexes alongside nucleophosmin, SBDS, and NIP7 provided the first evidence linking this nuclease to ribosome maturation.","evidence":"FLAG-tagged co-immunoprecipitation followed by mass spectrometry","pmids":["22540864"],"confidence":"Medium","gaps":["No reciprocal immunoprecipitation or direct functional validation of ISG20L2 within the complex","Specific pre-rRNA substrate(s) processed by ISG20L2 remained unknown"]},{"year":2022,"claim":"Revealing an unexpected non-catalytic function: ISG20L2 directly binds the proteasome inhibitor bortezomib and competes with PSMB5, establishing a drug-sequestration mechanism of resistance in myeloma.","evidence":"Surface plasmon resonance binding, biotinylated bortezomib pull-down, gain- and loss-of-function studies in vitro and in vivo","pmids":["36040812"],"confidence":"High","gaps":["Whether bortezomib binding is mediated by the DEDDh active site or a distinct pocket is unresolved","Relevance to resistance against other proteasome inhibitors not established"]},{"year":2023,"claim":"Defining ISG20L2's catalytic activity and immune function: ISG20L2 was shown to be a bona fide 3'-to-5' exoribonuclease with preferential activity on uridylated miRNAs, and its knockout in T cells disrupted immune synapse formation and expression of multiple checkpoint molecules, establishing it as an immunoregulatory enzyme.","evidence":"ISG20L2 knockout/silencing in T cells, biochemical substrate affinity assays, flow cytometry, immune synapse imaging","pmids":["37646974"],"confidence":"High","gaps":["Specific miRNA targets mediating immune phenotypes not individually validated","Whether exonuclease catalytic activity is required for all observed immune phenotypes not dissected by catalytic-dead mutants"]},{"year":2024,"claim":"Structural and mechanistic basis of rRNA processing: the 2.9 Å crystal structure of ISG20L2's nuclease domain revealed a canonical DEDDh active site, and mutagenesis coupled with pre-rRNA processing assays demonstrated its role in ITS1 removal during 18S maturation, directly linking nuclease activity to ribosome biogenesis and cell proliferation.","evidence":"X-ray crystallography at 2.9 Å, active-site and RNA-binding residue mutagenesis, pre-rRNA processing and proliferation assays","pmids":["38153123"],"confidence":"High","gaps":["No co-crystal structure with RNA substrate; mode of substrate recognition remains modeled","Relative contributions of ITS1 vs. ITS2/5.8S processing to proliferation phenotype not separated"]},{"year":2025,"claim":"Broadening the substrate repertoire: nucleotide-resolution sequencing after ISG20L2 inactivation revealed it is critical for 3'ETS removal from pre-rRNA and for U8 snoRNA precursor trimming, and that its loss disorganizes the nucleolar dense fibrillar component, establishing ISG20L2 as a multi-substrate rRNA/snoRNA processing enzyme essential for large subunit biogenesis.","evidence":"Loss-of-function with 3'-RACE high-throughput sequencing and nucleolar compartment imaging","pmids":["41261865"],"confidence":"High","gaps":["Whether ISG20L2 acts alone or requires cofactors for 3'ETS and U8 processing not determined","Structural basis for substrate selectivity among its multiple RNA targets remains unresolved"]},{"year":2025,"claim":"Connecting ISG20L2 to cancer cell phenotypes: ISG20L2 promotes lung adenocarcinoma proliferation and invasion through modulation of NKX2-1 expression, extending its functional relevance beyond ribosome biogenesis.","evidence":"Overexpression/depletion in A549 cells with proliferation and invasion assays","pmids":["40950659"],"confidence":"Medium","gaps":["Mechanism by which ISG20L2 regulates NKX2-1 expression (direct RNA processing vs. indirect) not established","Single cell line; generalizability to other lung cancer models untested"]},{"year":null,"claim":"Key open questions include how ISG20L2 achieves substrate selectivity among its diverse RNA targets (pre-rRNA, snoRNA, uridylated miRNAs), whether its catalytic activity is required for bortezomib sequestration, and what cofactors or complexes recruit it to specific processing steps.","evidence":"","pmids":[],"confidence":"Low","gaps":["No co-crystal structure with any RNA substrate","Cofactors and protein partners that direct ISG20L2 to specific substrates are uncharacterized","Whether catalytic-dead mutants retain the bortezomib-binding and immune-regulatory functions is untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[3,4,5]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[3,4,5]}],"localization":[{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[4,5]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[3]}],"complexes":[],"partners":["PSMB5"],"other_free_text":[]},"mechanistic_narrative":"ISG20L2 is a vertebrate-specific nucleolar 3'-to-5' exoribonuclease of the DEDDh/RNase T superfamily that plays essential roles in ribosome biogenesis and immune regulation. Its crystal structure reveals a DEDDh active site (Asp183, Glu185, Asp267, His322, Asp327) with an αβα fold; loss-of-function studies demonstrate that it processes multiple pre-rRNA intermediates—removing the 3' external transcribed spacer (3'ETS), trimming ITS1 after endonucleolytic cleavage during 18S maturation, contributing to ITS2/5.8S 3'-end maturation, and processing the U8 snoRNA precursor—and its inactivation impairs large ribosomal subunit formation, disorganizes the nucleolar dense fibrillar component, and reduces cell proliferation [PMID:38153123, PMID:41261865]. Outside the nucleolus, ISG20L2 is upregulated by TCR and type I interferon stimulation in T lymphocytes, where it preferentially degrades uridylated miRNA substrates and regulates immune synapse formation and expression of immunomodulatory receptors including PD-1, CTLA-4, and NKG2D [PMID:37646974]. ISG20L2 also directly binds bortezomib and competes with the proteasome subunit PSMB5, conferring proteasome-inhibitor resistance in multiple myeloma cells [PMID:36040812]."},"prefetch_data":{"uniprot":{"accession":"Q9H9L3","full_name":"Interferon-stimulated 20 kDa exonuclease-like 2","aliases":[],"length_aa":353,"mass_kda":39.2,"function":"3'-> 5'-exoribonuclease involved in ribosome biogenesis in the processing of the 12S pre-rRNA. Displays a strong specificity for a 3'-end containing a free hydroxyl group","subcellular_location":"Nucleus, nucleolus","url":"https://www.uniprot.org/uniprotkb/Q9H9L3/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/ISG20L2","classification":"Common Essential","n_dependent_lines":1166,"n_total_lines":1208,"dependency_fraction":0.9652317880794702},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"NPM1","stoichiometry":0.2},{"gene":"PSPC1","stoichiometry":0.2},{"gene":"RACK1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ISG20L2","total_profiled":1310},"omim":[{"mim_id":"611930","title":"INTERFERON-STIMULATED EXONUCLEASE GENE 20-KD-LIKE 2; ISG20L2","url":"https://www.omim.org/entry/611930"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"testis","ntpm":58.8}],"url":"https://www.proteinatlas.org/search/ISG20L2"},"hgnc":{"alias_symbol":["FLJ12671"],"prev_symbol":[]},"alphafold":{"accession":"Q9H9L3","domains":[{"cath_id":"3.30.420.10","chopping":"180-349","consensus_level":"high","plddt":97.0182,"start":180,"end":349}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H9L3","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H9L3-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H9L3-F1-predicted_aligned_error_v6.png","plddt_mean":72.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ISG20L2","jax_strain_url":"https://www.jax.org/strain/search?query=ISG20L2"},"sequence":{"accession":"Q9H9L3","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9H9L3.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9H9L3/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H9L3"}},"corpus_meta":[{"pmid":"21036379","id":"PMC_21036379","title":"Antiviral activities of ISG20 in positive-strand RNA virus infections.","date":"2010","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/21036379","citation_count":84,"is_preprint":false},{"pmid":"34026765","id":"PMC_34026765","title":"Identification of Key Genes With Differential Correlations in Lung Adenocarcinoma.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34026765","citation_count":18,"is_preprint":false},{"pmid":"22540864","id":"PMC_22540864","title":"Proteomic characterization of the human FTSJ3 preribosomal complexes.","date":"2012","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/22540864","citation_count":17,"is_preprint":false},{"pmid":"36040812","id":"PMC_36040812","title":"ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.","date":"2022","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36040812","citation_count":8,"is_preprint":false},{"pmid":"38153123","id":"PMC_38153123","title":"Molecular mechanism of human ISG20L2 for the ITS1 cleavage in the processing of 18S precursor ribosomal RNA.","date":"2024","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/38153123","citation_count":6,"is_preprint":false},{"pmid":"37646974","id":"PMC_37646974","title":"ISG20L2: an RNA nuclease regulating T cell activation.","date":"2023","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/37646974","citation_count":5,"is_preprint":false},{"pmid":"41261865","id":"PMC_41261865","title":"The 3'-5' exoribonuclease ISG20L2 contributes to 3' terminus maturation of 18S and 28S ribosomal RNAs.","date":"2025","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/41261865","citation_count":1,"is_preprint":false},{"pmid":"40950659","id":"PMC_40950659","title":"ISG20L2 as a driver in the proliferation and invasion of lung adenocarcinoma via NKX2-1 regulation.","date":"2025","source":"Translational cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/40950659","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":5442,"output_tokens":1832,"usd":0.021903},"stage2":{"model":"claude-opus-4-6","input_tokens":5117,"output_tokens":4521,"usd":0.207915},"total_usd":0.229818,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"ISG20L2 (along with ISG20L1) did not inhibit HCV replication, in contrast to ISG20, demonstrating that the closely related exonucleases lack ISG20's antiviral activity against positive-strand RNA viruses.\",\n      \"method\": \"Ectopic overexpression in cell culture with HCV replication assay\",\n      \"journal\": \"Virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional cell-based assay with defined readout, single study\",\n      \"pmids\": [\"21036379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ISG20L2 was identified as a component of human preribosomal complexes, co-immunoprecipitating with factors shared by nucleophosmin, SBDS, and NIP7 complexes, implicating ISG20L2 in ribosome biogenesis.\",\n      \"method\": \"FLAG-tagged co-immunoprecipitation followed by mass spectrometry (proteomic characterization)\",\n      \"journal\": \"Journal of proteome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP/MS study; no direct functional validation of ISG20L2 role in the complex\",\n      \"pmids\": [\"22540864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ISG20L2 directly binds bortezomib (confirmed by surface plasmon resonance) and competes with PSMB5 for bortezomib binding, thereby attenuating proteasome inhibition and conferring bortezomib resistance in multiple myeloma cells.\",\n      \"method\": \"Biotinylated bortezomib pull-down assay, surface plasmon resonance, gain- and loss-of-function studies in vitro and in vivo\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct binding confirmed by SPR, competition assay, and functional KD/OE with proteasome activity readout\",\n      \"pmids\": [\"36040812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ISG20L2 is upregulated in T lymphocytes upon TCR and type I IFN stimulation, acts as a 3'-to-5' exoribonuclease with preferential affinity for uridylated miRNA substrates, and regulates T cell activation markers (CD69, CD25, IL-2), immune synapse formation (CD3 synaptic accumulation, MTOC translocation), and expression of immunoregulatory molecules (AHR, NKG2D, CTLA-4, CD137, TIM-3, PD-L1, PD-1).\",\n      \"method\": \"ISG20L2 knockout and silencing in T cells, biochemical substrate affinity assays, flow cytometry, immune synapse imaging\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO with multiple defined cellular phenotypes and biochemical substrate characterization, multiple orthogonal methods\",\n      \"pmids\": [\"37646974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ISG20L2 is a 3'-5' exonuclease involved in ITS1 removal during 18S pre-rRNA maturation (in addition to previously known ITS2/5.8S rRNA processing). Crystal structure of the nuclease domain at 2.9 Å revealed a DEDDh motif (Asp183, Glu185, Asp267, His322, Asp327) with a typical αβα fold; mutagenesis mapped RNA substrate-binding residues; loss-of-function impairs ribosome biogenesis and cell proliferation.\",\n      \"method\": \"Crystal structure determination (2.9 Å), active-site mutagenesis, pre-rRNA processing assays, loss-of-function cellular proliferation assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mutagenesis and functional cellular validation in a single rigorous study\",\n      \"pmids\": [\"38153123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ISG20L2, a vertebrate-specific DEDDh RNase T superfamily member, is critical for efficient removal of the 3' external transcribed spacer (3'ETS) from pre-rRNA and for formation of large ribosomal subunits; its inactivation causes accumulation of 3'-extended pre-rRNAs and disorganization of the peripheral dense fibrillar component sub-nucleolar compartment. ISG20L2 also trims ITS1 after endonucleolytic cleavage at site 2 and contributes to 3' processing of U8 snoRNA precursor.\",\n      \"method\": \"Loss-of-function experiments combined with 3'-RACE high-throughput sequencing, nucleolar compartment imaging\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with nucleotide-resolution sequencing and multiple orthogonal phenotypic readouts\",\n      \"pmids\": [\"41261865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ISG20L2 promotes lung adenocarcinoma cell proliferation and invasion by modulating NKX2-1 expression, as shown by overexpression and depletion studies in A549 cells.\",\n      \"method\": \"Transient transfection overexpression/depletion, CCK-8 proliferation assay, Transwell invasion assay, flow cytometry, bioinformatics-guided target identification confirmed by cytological experiments\",\n      \"journal\": \"Translational cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, functional assays with defined phenotype but limited mechanistic depth on how ISG20L2 regulates NKX2-1\",\n      \"pmids\": [\"40950659\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ISG20L2 is a nucleolar 3'-to-5' DEDDh exoribonuclease (crystal structure resolved at 2.9 Å) that processes multiple pre-rRNA intermediates—including ITS1 removal during 18S maturation, 3'ETS removal required for large subunit biogenesis, and ITS2/5.8S 3'-end maturation—thereby supporting ribosome biogenesis and cell proliferation; outside the nucleolus it degrades uridylated miRNA substrates in activated T cells to regulate immune synapse formation and expression of key immunomodulatory receptors, and it can also directly bind bortezomib to compete with PSMB5 and confer proteasome-inhibitor resistance in myeloma cells.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ISG20L2 is a vertebrate-specific nucleolar 3'-to-5' exoribonuclease of the DEDDh/RNase T superfamily that plays essential roles in ribosome biogenesis and immune regulation. Its crystal structure reveals a DEDDh active site (Asp183, Glu185, Asp267, His322, Asp327) with an αβα fold; loss-of-function studies demonstrate that it processes multiple pre-rRNA intermediates—removing the 3' external transcribed spacer (3'ETS), trimming ITS1 after endonucleolytic cleavage during 18S maturation, contributing to ITS2/5.8S 3'-end maturation, and processing the U8 snoRNA precursor—and its inactivation impairs large ribosomal subunit formation, disorganizes the nucleolar dense fibrillar component, and reduces cell proliferation [PMID:38153123, PMID:41261865]. Outside the nucleolus, ISG20L2 is upregulated by TCR and type I interferon stimulation in T lymphocytes, where it preferentially degrades uridylated miRNA substrates and regulates immune synapse formation and expression of immunomodulatory receptors including PD-1, CTLA-4, and NKG2D [PMID:37646974]. ISG20L2 also directly binds bortezomib and competes with the proteasome subunit PSMB5, conferring proteasome-inhibitor resistance in multiple myeloma cells [PMID:36040812].\",\n  \"teleology\": [\n    {\n      \"year\": 2010,\n      \"claim\": \"Establishing functional divergence from ISG20: despite sequence homology, ISG20L2 lacks the antiviral exonuclease activity of ISG20, delimiting it as functionally distinct from the broader ISG20 family.\",\n      \"evidence\": \"Ectopic overexpression in cell culture with HCV replication readout\",\n      \"pmids\": [\"21036379\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single virus system (HCV); antiviral activity against other viral classes not tested\",\n        \"Endogenous substrates of ISG20L2 remained unidentified\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Placing ISG20L2 in the ribosome biogenesis pathway: proteomic identification of ISG20L2 in preribosomal complexes alongside nucleophosmin, SBDS, and NIP7 provided the first evidence linking this nuclease to ribosome maturation.\",\n      \"evidence\": \"FLAG-tagged co-immunoprecipitation followed by mass spectrometry\",\n      \"pmids\": [\"22540864\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No reciprocal immunoprecipitation or direct functional validation of ISG20L2 within the complex\",\n        \"Specific pre-rRNA substrate(s) processed by ISG20L2 remained unknown\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealing an unexpected non-catalytic function: ISG20L2 directly binds the proteasome inhibitor bortezomib and competes with PSMB5, establishing a drug-sequestration mechanism of resistance in myeloma.\",\n      \"evidence\": \"Surface plasmon resonance binding, biotinylated bortezomib pull-down, gain- and loss-of-function studies in vitro and in vivo\",\n      \"pmids\": [\"36040812\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether bortezomib binding is mediated by the DEDDh active site or a distinct pocket is unresolved\",\n        \"Relevance to resistance against other proteasome inhibitors not established\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defining ISG20L2's catalytic activity and immune function: ISG20L2 was shown to be a bona fide 3'-to-5' exoribonuclease with preferential activity on uridylated miRNAs, and its knockout in T cells disrupted immune synapse formation and expression of multiple checkpoint molecules, establishing it as an immunoregulatory enzyme.\",\n      \"evidence\": \"ISG20L2 knockout/silencing in T cells, biochemical substrate affinity assays, flow cytometry, immune synapse imaging\",\n      \"pmids\": [\"37646974\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Specific miRNA targets mediating immune phenotypes not individually validated\",\n        \"Whether exonuclease catalytic activity is required for all observed immune phenotypes not dissected by catalytic-dead mutants\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Structural and mechanistic basis of rRNA processing: the 2.9 Å crystal structure of ISG20L2's nuclease domain revealed a canonical DEDDh active site, and mutagenesis coupled with pre-rRNA processing assays demonstrated its role in ITS1 removal during 18S maturation, directly linking nuclease activity to ribosome biogenesis and cell proliferation.\",\n      \"evidence\": \"X-ray crystallography at 2.9 Å, active-site and RNA-binding residue mutagenesis, pre-rRNA processing and proliferation assays\",\n      \"pmids\": [\"38153123\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No co-crystal structure with RNA substrate; mode of substrate recognition remains modeled\",\n        \"Relative contributions of ITS1 vs. ITS2/5.8S processing to proliferation phenotype not separated\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Broadening the substrate repertoire: nucleotide-resolution sequencing after ISG20L2 inactivation revealed it is critical for 3'ETS removal from pre-rRNA and for U8 snoRNA precursor trimming, and that its loss disorganizes the nucleolar dense fibrillar component, establishing ISG20L2 as a multi-substrate rRNA/snoRNA processing enzyme essential for large subunit biogenesis.\",\n      \"evidence\": \"Loss-of-function with 3'-RACE high-throughput sequencing and nucleolar compartment imaging\",\n      \"pmids\": [\"41261865\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether ISG20L2 acts alone or requires cofactors for 3'ETS and U8 processing not determined\",\n        \"Structural basis for substrate selectivity among its multiple RNA targets remains unresolved\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Connecting ISG20L2 to cancer cell phenotypes: ISG20L2 promotes lung adenocarcinoma proliferation and invasion through modulation of NKX2-1 expression, extending its functional relevance beyond ribosome biogenesis.\",\n      \"evidence\": \"Overexpression/depletion in A549 cells with proliferation and invasion assays\",\n      \"pmids\": [\"40950659\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism by which ISG20L2 regulates NKX2-1 expression (direct RNA processing vs. indirect) not established\",\n        \"Single cell line; generalizability to other lung cancer models untested\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include how ISG20L2 achieves substrate selectivity among its diverse RNA targets (pre-rRNA, snoRNA, uridylated miRNAs), whether its catalytic activity is required for bortezomib sequestration, and what cofactors or complexes recruit it to specific processing steps.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No co-crystal structure with any RNA substrate\",\n        \"Cofactors and protein partners that direct ISG20L2 to specific substrates are uncharacterized\",\n        \"Whether catalytic-dead mutants retain the bortezomib-binding and immune-regulatory functions is untested\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [3, 4, 5]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [3, 4, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [4, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0008953854\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"PSMB5\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\nWait, I need to fix the pathway term. Let me correct: \"GO:0008953854\" is not a valid term. The correct Reactome pathway for RNA metabolism is \"R-HSA-8953854\".\n\n```json\n{\n  \"mechanistic_narrative\": \"ISG20L2 is a vertebrate-specific nucleolar 3'-to-5' exoribonuclease of the DEDDh/RNase T superfamily that plays essential roles in ribosome biogenesis and immune regulation. Its crystal structure reveals a DEDDh active site (Asp183, Glu185, Asp267, His322, Asp327) with an αβα fold; loss-of-function studies demonstrate that it processes multiple pre-rRNA intermediates—removing the 3' external transcribed spacer (3'ETS), trimming ITS1 after endonucleolytic cleavage during 18S maturation, contributing to ITS2/5.8S 3'-end maturation, and processing the U8 snoRNA precursor—and its inactivation impairs large ribosomal subunit formation, disorganizes the nucleolar dense fibrillar component, and reduces cell proliferation [PMID:38153123, PMID:41261865]. Outside the nucleolus, ISG20L2 is upregulated by TCR and type I interferon stimulation in T lymphocytes, where it preferentially degrades uridylated miRNA substrates and regulates immune synapse formation and expression of immunomodulatory receptors including PD-1, CTLA-4, and NKG2D [PMID:37646974]. ISG20L2 also directly binds bortezomib and competes with the proteasome subunit PSMB5, conferring proteasome-inhibitor resistance in multiple myeloma cells [PMID:36040812].\",\n  \"teleology\": [\n    {\n      \"year\": 2010,\n      \"claim\": \"Establishing functional divergence from ISG20: despite sequence homology, ISG20L2 lacks the antiviral exonuclease activity of ISG20, delimiting it as functionally distinct from the broader ISG20 family.\",\n      \"evidence\": \"Ectopic overexpression in cell culture with HCV replication readout\",\n      \"pmids\": [\"21036379\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single virus system (HCV); antiviral activity against other viral classes not tested\",\n        \"Endogenous substrates of ISG20L2 remained unidentified\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Placing ISG20L2 in the ribosome biogenesis pathway: proteomic identification of ISG20L2 in preribosomal complexes alongside nucleophosmin, SBDS, and NIP7 provided the first evidence linking this nuclease to ribosome maturation.\",\n      \"evidence\": \"FLAG-tagged co-immunoprecipitation followed by mass spectrometry\",\n      \"pmids\": [\"22540864\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No reciprocal immunoprecipitation or direct functional validation of ISG20L2 within the complex\",\n        \"Specific pre-rRNA substrate(s) processed by ISG20L2 remained unknown\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealing an unexpected non-catalytic function: ISG20L2 directly binds the proteasome inhibitor bortezomib and competes with PSMB5, establishing a drug-sequestration mechanism of resistance in myeloma.\",\n      \"evidence\": \"Surface plasmon resonance binding, biotinylated bortezomib pull-down, gain- and loss-of-function studies in vitro and in vivo\",\n      \"pmids\": [\"36040812\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether bortezomib binding is mediated by the DEDDh active site or a distinct pocket is unresolved\",\n        \"Relevance to resistance against other proteasome inhibitors not established\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defining ISG20L2's catalytic activity and immune function: ISG20L2 was shown to be a bona fide 3'-to-5' exoribonuclease with preferential activity on uridylated miRNAs, and its knockout in T cells disrupted immune synapse formation and expression of multiple checkpoint molecules, establishing it as an immunoregulatory enzyme.\",\n      \"evidence\": \"ISG20L2 knockout/silencing in T cells, biochemical substrate affinity assays, flow cytometry, immune synapse imaging\",\n      \"pmids\": [\"37646974\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Specific miRNA targets mediating immune phenotypes not individually validated\",\n        \"Whether exonuclease catalytic activity is required for all observed immune phenotypes not dissected by catalytic-dead mutants\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Structural and mechanistic basis of rRNA processing: the 2.9 Å crystal structure of ISG20L2's nuclease domain revealed a canonical DEDDh active site, and mutagenesis coupled with pre-rRNA processing assays demonstrated its role in ITS1 removal during 18S maturation, directly linking nuclease activity to ribosome biogenesis and cell proliferation.\",\n      \"evidence\": \"X-ray crystallography at 2.9 Å, active-site and RNA-binding residue mutagenesis, pre-rRNA processing and proliferation assays\",\n      \"pmids\": [\"38153123\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No co-crystal structure with RNA substrate; mode of substrate recognition remains modeled\",\n        \"Relative contributions of ITS1 vs. ITS2/5.8S processing to proliferation phenotype not separated\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Broadening the substrate repertoire: nucleotide-resolution sequencing after ISG20L2 inactivation revealed it is critical for 3'ETS removal from pre-rRNA and for U8 snoRNA precursor trimming, and that its loss disorganizes the nucleolar dense fibrillar component, establishing ISG20L2 as a multi-substrate rRNA/snoRNA processing enzyme essential for large subunit biogenesis.\",\n      \"evidence\": \"Loss-of-function with 3'-RACE high-throughput sequencing and nucleolar compartment imaging\",\n      \"pmids\": [\"41261865\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether ISG20L2 acts alone or requires cofactors for 3'ETS and U8 processing not determined\",\n        \"Structural basis for substrate selectivity among its multiple RNA targets remains unresolved\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Connecting ISG20L2 to cancer cell phenotypes: ISG20L2 promotes lung adenocarcinoma proliferation and invasion through modulation of NKX2-1 expression, extending its functional relevance beyond ribosome biogenesis.\",\n      \"evidence\": \"Overexpression/depletion in A549 cells with proliferation and invasion assays\",\n      \"pmids\": [\"40950659\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism by which ISG20L2 regulates NKX2-1 expression (direct RNA processing vs. indirect) not established\",\n        \"Single cell line; generalizability to other lung cancer models untested\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include how ISG20L2 achieves substrate selectivity among its diverse RNA targets (pre-rRNA, snoRNA, uridylated miRNAs), whether its catalytic activity is required for bortezomib sequestration, and what cofactors or complexes recruit it to specific processing steps.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No co-crystal structure with any RNA substrate\",\n        \"Cofactors and protein partners that direct ISG20L2 to specific substrates are uncharacterized\",\n        \"Whether catalytic-dead mutants retain the bortezomib-binding and immune-regulatory functions is untested\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [3, 4, 5]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [3, 4, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [4, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"PSMB5\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}